Literature DB >> 20382758

Cryptococcal interactions with the host immune system.

Kerstin Voelz1, Robin C May.   

Abstract

Opportunistic pathogens have become of increasing medical importance over the last decade due to the AIDS pandemic. Not only is cryptococcosis the fourth-most-common fatal infectious disease in sub-Saharan Africa, but also Cryptococcus is an emerging pathogen of immunocompetent individuals. The interaction between Cryptococcus and the host's immune system is a major determinant for the outcome of disease. Despite initial infection in early childhood with Cryptococcus neoformans and frequent exposure to C. neoformans within the environment, immunocompetent individuals are generally able to contain the fungus or maintain the yeast in a latent state. However, immune deficiencies lead to disseminating infections that are uniformly fatal without rapid clinical intervention. This review will discuss the innate and adaptive immune responses to Cryptococcus and cryptococcal strategies to evade the host's defense mechanisms. It will also address the importance of these strategies in pathogenesis and the potential of immunotherapy in cryptococcosis treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20382758      PMCID: PMC2901644          DOI: 10.1128/EC.00039-10

Source DB:  PubMed          Journal:  Eukaryot Cell        ISSN: 1535-9786


  205 in total

1.  In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans.

Authors:  K Truelsen; T Young; T R Kozel
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

2.  Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection.

Authors:  B C Fries; C P Taborda; E Serfass; A Casadevall
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation.

Authors:  Donatella Pietrella; Cristina Corbucci; Stefano Perito; Giovanni Bistoni; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; W H Welch
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

5.  Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis.

Authors:  A C Savoy; D M Lupan; P B Manalo; J S Roberts; A M Schlageter; L C Weinhold; T R Kozel
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

6.  Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.

Authors:  Marybeth A Maligie; Claude P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Cryptococcus neoformans. II. Phagocytosis by human leukocytes.

Authors:  G S Bulmer; M D Sans
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

Review 8.  Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans.

Authors:  Kazuyoshi Kawakami
Journal:  Jpn J Infect Dis       Date:  2004-08       Impact factor: 1.362

9.  Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung.

Authors:  John J Osterholzer; Rishi Surana; Jami E Milam; Gerald T Montano; Gwo-Hsiao Chen; Joanne Sonstein; Jeffrey L Curtis; Gary B Huffnagle; Galen B Toews; Michal A Olszewski
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

10.  Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages.

Authors:  Gary M Cox; Thomas S Harrison; Henry C McDade; Carlos P Taborda; Garrett Heinrich; Arturo Casadevall; John R Perfect
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more
  94 in total

Review 1.  Adaptation of Cryptococcus neoformans to mammalian hosts: integrated regulation of metabolism and virulence.

Authors:  Jim Kronstad; Sanjay Saikia; Erik David Nielson; Matthias Kretschmer; Wonhee Jung; Guanggan Hu; Jennifer M H Geddes; Emma J Griffiths; Jaehyuk Choi; Brigitte Cadieux; Mélissa Caza; Rodgoun Attarian
Journal:  Eukaryot Cell       Date:  2011-12-02

2.  Cryptococcus gattii infection dampens Th1 and Th17 responses by attenuating dendritic cell function and pulmonary chemokine expression in the immunocompetent hosts.

Authors:  Pornpimon Angkasekwinai; Nuntarat Sringkarin; Oratai Supasorn; Madtika Fungkrajai; Yui-Hsi Wang; Methee Chayakulkeeree; Popchai Ngamskulrungroj; Nasikarn Angkasekwinai; Kovit Pattanapanyasat
Journal:  Infect Immun       Date:  2014-06-30       Impact factor: 3.441

3.  Visualizing non-lytic exocytosis of Cryptococcus neoformans from macrophages using digital light microscopy.

Authors:  Sabriya Stukes; Arturo Casadevall
Journal:  J Vis Exp       Date:  2014-10-21       Impact factor: 1.355

4.  Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.

Authors:  Adepemi O Ogundeji; Carolina H Pohl; Olihile M Sebolai
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Neutrophil swarming toward Cryptococcus neoformans is mediated by complement and leukotriene B4.

Authors:  Donglei Sun; Meiqing Shi
Journal:  Biochem Biophys Res Commun       Date:  2016-07-09       Impact factor: 3.575

6.  Lipids Affect the Cryptococcus neoformans-Macrophage Interaction and Promote Nonlytic Exocytosis.

Authors:  Sabrina J Nolan; Man Shun Fu; Isabelle Coppens; Arturo Casadevall
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

Review 7.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

8.  A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.

Authors:  Arielle Butts; Louis DiDone; Kristy Koselny; Bonnie K Baxter; Yeissa Chabrier-Rosello; Melanie Wellington; Damian J Krysan
Journal:  Eukaryot Cell       Date:  2012-12-14

9.  Cryptococcus neoformans UGT1 encodes a UDP-Galactose/UDP-GalNAc transporter.

Authors:  Lucy X Li; Angel Ashikov; Hong Liu; Cara L Griffith; Hans Bakker; Tamara L Doering
Journal:  Glycobiology       Date:  2016-08-03       Impact factor: 4.313

10.  Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene.

Authors:  Kassandre Leongson; Vincent Cousineau-Côté; Mathieu Goupil; Francine Aumont; Serge Sénéchal; Louis Gaboury; Paul Jolicoeur; James W Kronstad; Louis de Repentigny
Journal:  Infect Immun       Date:  2013-01-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.